We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against other healthcare ...

NEW YORK (AP) -- Two analysts starting covering biotech drugmaker Chimerix Inc. with top ratings on Monday, pointing to the company's experimental drug CMX001. THE OPINION: Cowen & Co. analyst Phil ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Chimerix ( (CMRX)) has shared an ...

DURHAM, NC, February 14, 2011 – Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F ...

- Small Business Administration Rules that SIGA Technologies is Not a Small Business, Rendering It Ineligible for BARDA Contract RESEARCH TRIANGLE PARK, NC, November 7, 2010 - Chimerix, Inc., a ...

DURHAM, NC, March 28, 2011 – Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, announced today that Timothy W. Trost has joined the company as Senior Vice ...

(Reuters) - Chimerix Inc said on Friday it had been awarded a contract worth up to $25.3 million by Canada for its smallpox drug, likely to used to treat monkeypox as the viral infection spreads ...

A small biotechnology company agreed yesterday to provide their experimental, antiviral drug for the treatment of a seven-year-old Virginia boy, Joshua Hardy, who is currently suffering from a ...

Chimerix (NASDAQ:CMRX) just reported results for the first quarter of 2024. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports.

Shares of Chimerix Inc. shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to Emergent ...

Social media campaigns for "compassionate use" access to drugs still in clinical trials got a big boost yesterday. The mother of Josh Hardy, a now-8-year-old boy suffering with cancer for nearly all ...